339 related articles for article (PubMed ID: 30715357)
1. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
Eichelberger MC; Monto AS
J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
[TBL] [Abstract][Full Text] [Related]
3. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
Krammer F; Palese P
J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
5. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins.
Ross TM
J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379
[TBL] [Abstract][Full Text] [Related]
6. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
Rudraraju R; Mordant F; Subbarao K
J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
[No Abstract] [Full Text] [Related]
7. Antibody Determinants of Influenza Immunity.
Crowe JE
J Infect Dis; 2019 Apr; 219(Suppl_1):S21-S29. PubMed ID: 30715373
[TBL] [Abstract][Full Text] [Related]
8. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017.
Catani JPP; Smet A; Ysenbaert T; Vuylsteke M; Bottu G; Mathys J; Botzki A; Cortes-Garcia G; Strugnell T; Gomila R; Hamberger J; Catalan J; Ustyugova IV; Farrell T; Stegalkina S; Ray S; LaRue L; Saelens X; Vogel TU
Elife; 2024 May; 12():. PubMed ID: 38805550
[TBL] [Abstract][Full Text] [Related]
9. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
[TBL] [Abstract][Full Text] [Related]
10. Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine.
Crank MC; Mascola JR; Graham BS
J Infect Dis; 2019 Apr; 219(Suppl_1):S107-S109. PubMed ID: 30715413
[No Abstract] [Full Text] [Related]
11. Making Universal Influenza Vaccines: Lessons From the 1918 Pandemic.
Morens DM; Taubenberger JK
J Infect Dis; 2019 Apr; 219(Suppl_1):S5-S13. PubMed ID: 30715352
[TBL] [Abstract][Full Text] [Related]
12. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine.
Johansson BE
Vaccine; 1999 Apr; 17(15-16):2073-80. PubMed ID: 10217609
[TBL] [Abstract][Full Text] [Related]
13. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies.
Gao J; Couzens L; Burke DF; Wan H; Wilson P; Memoli MJ; Xu X; Harvey R; Wrammert J; Ahmed R; Taubenberger JK; Smith DJ; Fouchier RAM; Eichelberger MC
mBio; 2019 Apr; 10(2):. PubMed ID: 30967460
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Neuraminidase Immunogenicity of Influenza A Viruses by Rewiring RNA Packaging Signals.
Zheng A; Sun W; Xiong X; Freyn AW; Peukes J; Strohmeier S; Nachbagauer R; Briggs JAG; Krammer F; Palese P
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493826
[TBL] [Abstract][Full Text] [Related]
15. Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.
Broecker F; Zheng A; Suntronwong N; Sun W; Bailey MJ; Krammer F; Palese P
J Virol; 2019 Sep; 93(18):. PubMed ID: 31375573
[TBL] [Abstract][Full Text] [Related]
16. Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Piepenbrink MS; Nogales A; Basu M; Fucile CF; Liesveld JL; Keefer MC; Rosenberg AF; Martinez-Sobrido L; Kobie JJ
mBio; 2019 Mar; 10(2):. PubMed ID: 30862743
[TBL] [Abstract][Full Text] [Related]
17. Changing perspective on immunization against influenza.
Johansson BE; Brett IC
Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
[TBL] [Abstract][Full Text] [Related]
18. Progress in the Development of Universal Influenza Vaccines.
Sun W; Luo T; Liu W; Li J
Viruses; 2020 Sep; 12(9):. PubMed ID: 32957468
[TBL] [Abstract][Full Text] [Related]
19. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
Marcelin G; Sandbulte MR; Webby RJ
Rev Med Virol; 2012 Jul; 22(4):267-79. PubMed ID: 22438243
[TBL] [Abstract][Full Text] [Related]
20. Evolution and Antigenic Advancement of N2 Neuraminidase of Swine Influenza A Viruses Circulating in the United States following Two Separate Introductions from Human Seasonal Viruses.
Kaplan BS; Anderson TK; Chang J; Santos J; Perez D; Lewis N; Vincent AL
J Virol; 2021 Sep; 95(20):e0063221. PubMed ID: 34379513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
